Copyright © Inderes 2011 - present. All rights reserved.
  • Latest
  • Markets
    • Stock Comparison
    • Financial Calendar
    • Dividends Calendar
    • Research
    • Articles
  • inderesTV
  • Portfolio
  • Forum
  • Q&A
  • About Us
    • Our Coverage
    • Team

Nanoform Finland

0.87

 

EUR

 

+16 %

3,527 following

NANOFH

First North Finland

Medical Equipment & Services

Health Care

Overview
Ownership
Investor consensus

Nanoform Finland is a medical technology company. The company specializes in the research and development of technical products used to create nanoparticles in pharmaceuticals. The technology is used as a complement in the production process and is used for the treatment of diseases such as ALS and Alzheimer's. The customers consist of companies in the global pharmaceutical industry. Nanoform Finland mainly operates in the Nordic market and is headquartered in Helsinki.

Read more
Market cap
74.41M EUR
Turnover
741.65K EUR
Revenue
2.57M
EBIT %
-874.71 %
P/E
-
Dividend yield-%
-
Financial calendar
21/8
2025

Interim report Q2'25

20/11
2025

Interim report Q3'25

26/2
2026

Annual report '25

All
Research
Webcasts
Press releases
ShowingAll content types
Press release6/12/2025, 5:10 AM

Nanoform starts Pivotal Human Bioequivalence Studies of Nanoenzalutamide

Nanoform Finland
Press release6/3/2025, 5:10 AM

DEVELOPMENT OF NANOFORMED TRASTUZUMAB FOR SUBCUTANEOUS INJECTION TO BE PRESENTED AT DDF SUMMIT IN BERLIN

Nanoform Finland
Regulatory press release5/30/2025, 6:45 AM

Nanoform Finland Plc – Manager’s Transactions – Albert Hæggström

Nanoform Finland

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Regulatory press release5/30/2025, 6:45 AM

Nanoform Finland Plc – Manager’s Transactions – Peter Hänninen

Nanoform Finland
Press release5/28/2025, 2:00 PM

POSITIVE NANOFORM BIOLOGICS RESPIRATORY DATA TO BE PRESENTED AT DRUG DELIVERY AND FORMULATION SUMMIT

Nanoform Finland
Regulatory press release5/20/2025, 5:10 AM

Nanoform Q1 2025 report: Deal mosaic emerge and commercial value clearly seen in our CESS® technology

Nanoform Finland
Regulatory press release5/20/2025, 4:45 AM

INSIDE INFORMATION MADE PUBLIC: NANOFORM PARTNERS WITH TWO SPECIALIST HEALTHCARE INVESTORS TO DEVELOP AND COMMERCIALISE NANOENCORAFENIB

Nanoform Finland
Press release5/6/2025, 8:00 AM

Invitation to Nanoform’s Q1 2025 Report Presentation

Nanoform Finland
Regulatory press release4/15/2025, 11:10 AM

Resolutions of the Constitutive Meeting of the Board of Directors of Nanoform Finland Plc

Nanoform Finland
Regulatory press release4/15/2025, 11:00 AM

Resolutions of Nanoform Finland Plc's Annual General Meeting on April 15, 2025

Nanoform Finland
Regulatory press release3/17/2025, 3:15 PM

Nanoform: Notice to the Annual General Meeting of NANOFORM FINLAND Plc

Nanoform Finland
Nanoform, Audiocast with teleconference, Q4'24
Webcast2/27/2025, 1:00 PM

Nanoform, Audiocast with teleconference, Q4'24

Nanoform Finland
Regulatory press release2/27/2025, 6:10 AM

Nanoform 2024 report: Deal discussions around product kernels intensify

Nanoform Finland
Press release2/13/2025, 9:00 AM

Invitation to Nanoform's Q4 and FY 2024 Report Presentation

Nanoform Finland
Regulatory press release12/18/2024, 3:01 PM

Nanoform Finland Plc - Managers' transactions - Antonio Da Silva

Nanoform Finland
Regulatory press release12/18/2024, 3:01 PM

Nanoform Finland Plc - Manager's Transactions - Peter Hänninen

Nanoform Finland
Regulatory press release12/18/2024, 3:01 PM

Nanoform Finland Plc - Manager's Transactions - Edward Hæggström

Nanoform Finland
Regulatory press release12/18/2024, 3:01 PM

Nanoform Finland Plc - Manager's Transactions - Albert Hæggström

Nanoform Finland
Regulatory press release12/18/2024, 3:00 PM

The Board of Directors of Nanoform Finland Plc decided on issue of stock options under an option program open to all employees

Nanoform Finland
Life Science Companies as Investments | Life Science Night Dec. 2, 2024
Video12/2/2024, 2:00 PM

Life Science Companies as Investments | Life Science Night Dec. 2, 2024

Antti Siltanen, Life Science Analyst, PhD, talks about life science companies as investments.

Aiforia TechnologiesBBS-Bioactive Bone SubstitutesBioretecBiohitFaron PharmaceuticalsModulightNexstimOrionBittiumDetection TechnologyOptomedRevenio GroupNightingale HealthHerantis PharmaNanoform Finland
Find us on social media
  • Inderes Forum
  • Youtube
  • Instagram
  • Facebook
  • X (Twitter)
Get in touch
  • info@inderes.se
  • +46 8 411 43 80
  • Vattugatan 17, 5tr
    111 52 Stockholm
Inderes
  • About us
  • Our team
  • Careers
  • Inderes as an investment
  • Services for listed companies
Our platform
  • FAQ
  • Terms of service
  • Privacy policy
  • Disclaimer
Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.